Member Info for Doc.Daneeka

Synairgen are certainly fortunate if Casanovalabs is designing / adapting the assay for the P2s. World leaders in their field and undoubtedly the best partnership you could imagine. Let's not think it's the whole gig though. Traditional methods of data analysis are still the main part of the package, and we know what direction that data points in. Auto-abs testing will help to identify a maximum of between 10% - 15% of ICU patients who have them on arrival, or develop them in hospital, but as this study shows those patients may not have more severe outcomes than other severely ill patients.

Bastard et al December 2022 " A total of 925 critically ill COVID-19 patients were included in the cohort between March 2020 and May 2021 and had serum samples analysed for neutralization ability of anti-IFN auto-Abs. The median age of the patients included in the whole cohort was 62 years, 70% of whom were male. Hypertension (51.2%) and obesity (43.0%) were the most frequent comorbidities, as expected in critically ill COVID-19 patients

We found auto-Abs neutralizing type I IFNs in 96 patients of the cohort (10.3%, 95% CI [8.4–12.3])

In conclusion, auto-Abs against type I IFNs were found in at least 10% of critically ill COVID-19 patients, but in contrast with previous studies including both ICU and non-ICU patients, were not associated with increased mortality in this cohort of ICU patients. Further studies should aim at exploring an impaired type I IFN production or response in critically ill COVID-19 patients without positive auto-Abs, as they exhibit the same clinical features and outcomes than those who carry neutralizing auto-Abs. Routine screening of auto-Abs against type I IFN might be of interest before ICU admission to predict the risk of clinical worsening, as previously demonstrated, but seems to be of limited interest in the ICU setting to improve outcome prediction. Whether targeted treatment strategies should be initiated in patients with positive auto-Abs should be determined by future studies.

https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-022-01095-5

Those were the days. Ndn and Andybe4 predicting doom - the fools.

Afreed TP this will be unrecognisbable to the loosely targeted Sprinter trial - which as I've said many times was designed when the scientists and RM still believed they had a mass population drug on their hands. Many reasons to lament Sprinter - but perhaps the most significant now being the decision not to collect samples, as mentioned by Jd earlier - which was made because of the complications of multi-jurisdictional global trialing. Shame though as so many of the sites were in countries where it would have been an easy task to accomplish.

Not trawling through the ashes of a long cold fire - but imagine how much further along we'd be with all that data. !!

So - using existing assays to test UNIVERSAL patients blood - and then hopefully something tailormade from this and other data using Auto-abs & IFns to test patients before inclusion on the P2s. ( not the Ventilator trial of course )

There is of course the likelihood that UNIVERSAL will have a good percentage of younger, fitter patients who will be at the bottom end of the Auto-ab spectrum. They just need to be over 18 and suffering from a confirmed respiratory viral infection to be admitted. That's all - and the data about auto-abs and IFns shows a very steep curve in older patients - as many as 15/20% at the top end of severely ill very old and co-morbid patients, but at the other end of the spectrum less than 1% in the healthy general population.

We might assume that the P2 inclusion criteria will include age ( over 60/65 ) and co-morbidities & oxygen - and hopefully an additional assay test to spot those who are at greatly increased risk. UNIVERSAL may not offer a great deal - in terms of headline %s - because the data will include so many who aren't going to get ill - but hopefully it'll have enough to confirm that Auto-abs affect outcomes for all the other conditions in the study, for which there is no or little data.

UNIVERSAL

" In stage 2, further nose and throat swabs and blood samples will be collected on days 1, 3 and 7 of enrolment "

(stage 1 is the confirmatory test that they have a respiratory viral infection )

Did the first set of data include details of ages / co-morbidities of the 300 ? Not asking anyone to do my research but if you know please post.

Thanks Brand " They are absolutely testing Universal patients for auto-abs. Perhaps it's the thermo Fischer test, perhaps is the Casanova test, but that data is definitely being collected. "

Is this in thye Universal protocol ?

Jint - than ks for the clarification. It was Brand's last comment

"We still haven't seen auto abs data from Universal - curious if this is the test they have been using "

Are we sure they're using any auto-ab assay on UNIVERSAL ? The data already exists to show the % of general population and Covid 19 patients who have them, and the age breakdown, and we know also that IFn function is affected by auto-abs - but it's not something UNIVERSAL can test is it - or at least with such a wide inclusion criteria it's unlikely to show %s anywhere near those gained from the large post hoc tests.

What we need for the P2s are pre trial admission tests that will weed out the patients who don't need SNG001. As there's no drug involved in UNIVERSAL they'd be unlikely to produce better results than those produced by Casanovlabs already. I imagined they were working with Casanovalab for a diagnostic assay to be used in our P2s not in UNIVERSAL which is allowing admission to anyone with a positive test for a respiratory virus.

Apologies if I've misunderstood this - which i almost certainly have, judging by the excitement here today.

I'll be there Sparky. Hoping for a quid at the end of this but will settle for 40p

Jint "I carried out a search for IP patent applications for Mirimus and autoantibodies, nothing found. This could suggest they’re licensing the IP, question is, is it the Casanova assay? Balance of probabilities points to it could be likely. "

You don't think there's a chance they haven't got one yet ? As they happily admit on their website.

I dunno Brand - they look like they're miles behind Casanovalabs. I mean this is from their website - it's not a news piece and they're not shown as having any "products" at all. I mean - do they ? They're at the computer/algorithm stage and also don't seem to have anything to say about Ifns - not on this page anyway - which is what makes Casanovalabs so directly relevant. it's all in the same ballpark of course - but you know it's a very big ballpark, and remembering how long it takes to peform cliniical trials and gain authorisation...... And how little time there is before our trials begin.

"Mirimus has developed an advanced computational, machine-learning algorithm to predict proteins that might be neutralized by pathogenic autoantibodies. We are now in the process of performing experimental validation of select targets with the goal of building a panel of advanced diagnostic immunoassays. Our goal is to improve patient outcomes through early and accurate detection, personalized treatment approaches, and a deeper understanding of the underlying mechanisms. "

https://www.ventureradar.com/search/ranked/autoantibodies/#

5 minutes on Google shows Venture Radar has 43 companies listed as working with autoabs.

Tommy TP wrote that after you began the daily bear baiting. And after about the 50th personal insult you've levelled at him.

Stick in your lane and you'll be fine. Keep your stupid theories about who might be real and who might be looking for a trade at 5 and a half p to yourself. Try not to insult posters who've been here since Magic Monday - long before you were even a twinkle in TFG's eye.

That's me done on this. If anyone wants to discuss things that are genuinely relevant to Synairgen I'll be looking in. If anyone has links to genuinely relevant studies that might support SNG - I'll be looking in.

" But I’m not going to join in Yours and Doc D bating "

The irony - after you began the bating with your pathetic

"Interesting .... Nice to see some posters still do research to help this board rather than filling the board with the same old repetitive tropes "

The link was worth only "interesting" - because you know it's of bu.gger all relevance - but it gave you a chance to get your pathetic little stick out and start poking. Hopefully you've learned a lesson.

And don't kid yourselves you're engaged in "research" Any fool can spend 30 minutes trawling through Autoantibody searches and picking one that seems to fit the bill. Gunto knows absolutely zero about Mirmus - or he'd provide context for the post and suggest the relevance. Are Synairgen connected to this company - are they doing something in our area - or does the hope that Casanovalbs is engaged with Synairgen allow you to post every single piece of junk in this very broad area of research that many many companies are engaged in.

It really is pathetic. Read my piece from earlier on. I don't claim it as research but it's more relevant to our drug - our story and the climate that will await SNG if it proves its worth - than all of your tangential pseudo-science

Oh go away - it's become so Td-ous. Say well done to Gunto by all means but leave everyone else's posts alone.

You want to pick fights - did it yesterday and it led to another day of unpleasantness.

Keep fluffing for RM if you must - drench the board with ridiculously irrelevant links to studies into Cancer genome slicing or links to a website that thinks Synairgen is a startup - but let the rest of us enjoy a balanced debate.

Focusing on a new Chinese drug Simnotrelvir - and our old friend Ensitrelvir - which was the first drug on STRIVE ( the US platform trial we had such hopes for in late 22)

Shionogi's Ensitrelvir is a protease inhibitor - it has already concluded an 1800 patient trial which showed showed viral clearance 36hrs faster than placebo and a consequent 45% risk reduction in Long Covid. Approved in November 22 in Japan - but the FDA wanted more and recruitment for Strive began in June last year. Seen as a clean alternative to Paxlovid which has so many drug interactions, but difficult to know how it will be performing in the current climate.

Interesting the Time gives it such a puff but Eric Topol says don't hold your breath - as the road will be long and hard for new antivirals in the current climate. Paxlovid was EUAd in 5 weeks in 2021 - but those were different times.

We once considered this a rival but it's not now as SNG's future seems to lie firmly in ICU - whereas both of these cheap new drugs are to be taken within 3 days of a positive test. Still possible of course that STRIVE might look again at SNG001 after successful P2s. Not getting any hopes up for this after previous disappointments but It's not impossible. Of course were it to happen, and the P3 is achieved through the fully funded STRIVE, Synairgen would keep full financial control of the drug. If Covid has faded somewhat from view in a whole population sense - it is still killing lots of older and vulnerable patients - and anything that helps that population - and helps clear ICU beds - will still be of interest.

https://time.com/6588624/covid-19-antiviral-treatments-us/

Sorry - and Sakura 7 after the "bust in 3 years " remark

Fruits we should stop this for the sake of everyone else on the bb. I've never defended anyone except genuine LTHs who somehow find themselves in your cross hairs or on Tommy's growing list. On his list only Mrcosts and Prof are what might be described as trolls or traders.

Make your posts as you wish and I'll make mine. I'll be polite and cordial but the instant you start all that finger wagging nonsense again or say I'm anything other than an LTH with an alternate view. People are allowed to be disappointed with many many things since SG016, and they're allowed to express that disappointment until tangible proof arrives that the company knows how to save this situation.

Fruits you've been insulting me and others for years with your nonsense about teams and multiple accounts and I'm finally giving it back to you. Keep a civil tongue in your head and reply with substance to the actual posts and you might do better.

Tom - you're cutting and pasting again. Tedious and irrelevant. And complaining about my trial protocol suggestions when you accused me of plagiarism when i originally made that post aboiut how it might all come together. Hahaha

And 2 years is fine. They've had to change tack - talk to partners - work out which of the many possible ways forward is the best. ( I mean RM threw out Ventilated patients from a completelky clear sky in the interim update - where did that come from as one of the 2 main investigatative routes forward ? ) UNIVERSAL may have been Synairgen's idea - and that had to get started and then deliver useful data.

So it's fine if we are where we are - but we should know a lot more about what's been going on - they really could explain what it was that meant the trials couldn't start last year - and because of the calamity of Feb 22 - and this ongoing sense that the whole company is still in the bunker - plenty of people on here just don't trust them to get it right and are concerned that at the end of all this SNG will bgiven away for nothing.

Auf Wiedersehn